Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drugs whose agreements from the national centralized procurement have expired, with 13 products proposed for selection in this round [1][2]. Group 1: Procurement Details - The company has submitted applications for the continuation procurement organized by Jiangsu, Henan, and Guangdong provinces [1]. - The proposed selected products include 12 that were previously selected in the first to eighth batches of national centralized procurement and one new product, Paricalcitol Injection [1]. - The sales revenue from these products is projected to be approximately 651.20 million yuan in 2024, accounting for 48.25% of the company's total revenue for that year [1]. Group 2: Impact on Revenue - For the period from January to September 2025, the expected sales revenue from these products is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [1]. - The procurement cycle will last until December 31, 2028, during which medical institutions will prioritize the selected drugs, ensuring the completion of agreed procurement volumes [2]. Group 3: Market Stability - The overall pricing of the procurement is expected to remain stable or decrease further, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a price decrease compared to original sales prices, the selection of 13 products allows the company to maintain its market share and enhance the accessibility of these drugs [2].

Important Matters - Evert plans to acquire 100% of Shengpu shares, with stock resuming trading on February 10 [1] - Hainan Mining intends to acquire 69.9% stake in Fengrui Fluorine Industry, with stock resuming trading on February 10 [1] - Runtou Co., which has seen its core product disperse dye prices rise by approximately 5000 yuan per ton recently, has achieved two consecutive trading limit increases [1] - Zhejiang Longsheng has announced another price adjustment for certain types of disperse dyes on February 8, with price sustainability dependent on supply and demand [1] - Taisheng Wind Power's rocket fuel storage tank production line is designed for an annual capacity of 60 tanks, expected to be operational by mid-2026 [1] - Dingsheng Technology has signed a cooperation framework agreement with Huineng Technology for solid-state batteries and the new energy industry [1] - Microelectrophysiology has received EU MDR certification for its magnetic navigation ablation catheter and star high-density mapping catheter [1] - Yuandong Bio has completed the first dosing of the Phase I clinical trial for the EP-0210 monoclonal antibody injection [1] - Xinyi Sheng has mass-produced and delivered 1.6T optical modules, while advancing the development of 3.2T, 6.4T, and 12.8T products [1] Investments, Contracts, and Collaborations - Mengguli plans to invest 929 million yuan to build a project for an annual production of 30,000 tons of lithium-ion battery cathode materials [1] - Zhiguang Electric's subsidiary has signed a 1.004 billion yuan contract for energy storage systems [1] - Daily Interaction's wholly-owned subsidiary intends to increase capital by 10 million yuan in Yuntong Shuda [1] - Jinhui Co. plans to acquire 100% of Fusheng Mining for 210 million yuan, which holds a gold mining right with an annual production capacity of 50,000 tons [1] - Yuanjie Technology intends to invest 1.251 billion yuan to build a second-phase research and production base for optoelectronic communication semiconductors, focusing on high-speed optical chips [1] - Zhongke Shuguang plans to issue convertible bonds to raise no more than 8 billion yuan for advanced computing cluster systems aimed at artificial intelligence [1] Share Buybacks - Huitai Medical plans to repurchase shares worth 150 million to 200 million yuan for employee stock ownership plans or equity incentives [2] - Kaiying Network intends to repurchase shares worth 100 million to 200 million yuan [2] - Dianzhi Technology plans to repurchase shares worth 100 million to 200 million yuan [2]

Group 1: Pharmaceutical Industry - The pharmaceutical index increased by 0.14%, outperforming the CSI 300 index by 1.47% during the week [2][6] - The report highlights the potential of molecular glue technology to target "undruggable" proteins, expanding the scope for innovative drug development [8][9] - Recommended stocks in the innovative drug sector include Heng Rui Medicine, China Biologic Products, and Yuan Dong Biology, among others [11][9] Group 2: Construction and Building Materials - Major engineering projects are identified as a key focus for the "14th Five-Year Plan," with significant investments planned across various provinces [13][14] - The report notes that infrastructure projects will dominate investment, with substantial funding allocated to transportation, municipal, and energy sectors [14] - The issuance of special bonds has increased significantly, with a total of 5,164.55 billion yuan issued as of February 8, 2026, marking a year-on-year increase of 125.35% [15] Group 3: Real Estate - The Shanghai government has initiated the acquisition of second-hand homes for rental housing projects, indicating a strategic move to stabilize the real estate market [19][21] - New home sales in 42 key cities totaled 1.48 million square meters, a slight decrease of 0.1% week-on-week, while second-hand home sales fell by 3.0% [20][19] - The report suggests that the real estate market is entering a phase of structural differentiation, with high-quality housing expected to see increased demand [23] Group 4: Overseas and Education Research - The first round of negotiations between the US and Iran concluded, with market sentiment shifting towards risk assets, particularly in AI and commercial aerospace sectors [26][30] - Bloom Energy reported better-than-expected earnings, with Q4 2025 revenue reaching $777.8 million, a year-on-year increase of 35.9% [26] - The quantum computing sector is gaining attention, with NERSC announcing a call for proposals utilizing neutral atom quantum processors [28]

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced the completion of the first dosing of the EP-0210 monoclonal antibody injection in a Phase I clinical trial for treating inflammatory bowel disease, indicating progress in its drug development pipeline [1][3]. Group 1: Drug Overview - EP-0210 monoclonal antibody injection is a humanized IgG1 monoclonal antibody targeting TNF-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease by blocking TL1A-mediated pro-inflammatory signaling pathways [1][2]. - Preclinical studies have shown that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, demonstrating better target activity and efficacy compared to the foreign competitor RVT-3101 [2]. Group 2: Clinical Trial Details - The Phase I clinical trial for EP-0210 received formal approval from the National Medical Products Administration in January 2026, with the trial focusing on safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants [3]. - As of the announcement date, the first dosing in the single-dose administration phase of the trial has been completed [3].

Core Viewpoint - Yuan Dong Bio (688513) announced that its wholly-owned subsidiary Chengdu Youluo Biotechnology Co., Ltd. has initiated Phase I clinical trials for its monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first patient dosing recently completed [1] Company Summary - EP-0210 is a humanized IgG1 monoclonal antibody that targets TNF-like ligand 1A (TL1A), aiming to treat inflammatory bowel disease by effectively binding to TL1A and blocking pro-inflammatory signaling pathways [1] - The development of TL1A antibody drugs is one of the most closely watched emerging targets in the field of inflammatory bowel disease, with no similar drugs currently available on the market globally [1] Industry Summary - The fastest global development progress for TL1A-targeting drugs is being made by Merck, Sanofi, and Roche/Pfizer, all of which have TL1A antibody drugs in Phase III clinical trials [1] - In China, companies such as 3SBio, ZhiXiang JinTai, and HuaShen ZhiYao have also entered Phase I clinical trials for similar TL1A-targeting drugs [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

证券代码：688513 证券简称：苑东生物 公告编号：2026-003 EP-0210 单抗注射液是一款靶向人肿瘤坏死因子样配体 1A（TNF-like ligand 1A，TL1A）的人源化 IgG1 单克隆抗体药物，拟定适应症为炎症性肠病，其作 用机制是通过高效结合人 TL1A，阻止 TL1A 介导的促炎症信号通路，从而发挥 治疗炎症性肠病的作用。 临床前研究表明，EP-0210 单抗注射液药效作用机制明确，在多种炎症性肠 病体内模型中药效显著，具有良好的安全性和有效性；其在靶点活性、体内药效 等方面优于国外同靶点竞品 RVT-3101，有望为炎症性肠病患者带来安全有效的 更多选择。 二、药品 I 期临床试验相关情况 EP-0210 单抗注射液于 2026 年 1 月收到国家药品监督管理局正式批准签发 的《药物临床试验批准通知书》（通知书编号：2026LP00264）。在获得国家药 品监督管理局的药物临床试验批准后，公司启动"EP-0210 单抗注射液在中国健 康成年受试者中的安全性、耐受性和药动学特征的随机、双盲、安慰剂对照、剂 量递增的 I 期临床研究"（临床试验登记号：CTR20260325）。该研 ...

Core Viewpoint - Yuan Dong Biotech (688513.SH) has announced that its wholly-owned subsidiary Chengdu Youluo Biotech Co., Ltd. has initiated a Phase I clinical trial for its self-developed monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first subject having been dosed recently [1] Group 1: Product Development - EP-0210 is a humanized IgG1 monoclonal antibody targeting human tumor necrosis factor-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease [1] - The mechanism of action involves high-affinity binding to TL1A, blocking the pro-inflammatory signaling pathways mediated by TL1A, thereby providing therapeutic effects for inflammatory bowel disease [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, showing good safety and effectiveness [1] - EP-0210 exhibits superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101, potentially offering safer and more effective options for patients with inflammatory bowel disease [1]

Group 1 - The core point of the article is that Yuandong Biotech (688513.SH) announced the completion of the first dosing of its monoclonal antibody drug EP-0210 in a Phase I clinical trial for the treatment of inflammatory bowel disease [2] - The drug EP-0210 is a humanized IgG1 monoclonal antibody targeting the tumor necrosis factor-like ligand 1A (TL1A) [2] - EP-0210 demonstrates superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101 [2]